Kiadis issues options to newly hired employees to meet its existing obligations
20 Novembro 2020 - 3:00AM
Kiadis issues options to newly hired employees to meet its existing
obligations
This is a press release by Kiadis Pharma N.V.
(Kiadis), pursuant to the provisions of Sections 5
paragraphs 4 and 5 and 6 paragraph 2 of the Dutch Decree on Public
Takeover Bids (Besluit openbare biedingen Wft) (the
Decree) in connection with the intended public
offer by Sanofi for all the issued and outstanding ordinary shares
in the capital of Kiadis (the Offer). This
announcement does not constitute an offer, or any solicitation of
any offer, to buy or subscribe for any securities. Any offer will
be made only by means of an offer memorandum approved by the Dutch
Authority for the Financial Markets (Autoriteit Financiële Markten)
and recognized by the Belgian Authority for the Financial Markets
(Autoriteit voor Financiële Diensten en Markten). This announcement
is not for release, publication or distribution, in whole or in
part, in or into, directly or indirectly, the United States, Canada
and Japan or in any other jurisdiction in which such release,
publication or distribution would be unlawful.
Kiadis issues options to newly hired
employees to meet its existing obligations
Amsterdam, The Netherlands, November 20,
2020 – Kiadis Pharma N.V. (“Kiadis” or the “Company”) (Euronext
Amsterdam and Brussels: KDS), today announces that,
following the announcement on November 2, 2020 that Kiadis and
Sanofi reached conditional agreement on the Offer, the Dutch public
offer rules require Kiadis to announce in a press release all
transactions by Kiadis relating to the ordinary shares in its
capital including the issuance of options or shares to employees.
Accordingly, Kiadis makes the disclosures below.
Pursuant to commitments entered into prior to
November 2, 2020, Kiadis will, in the period between today and
January 1, 2021, issue a total of 13,500 options to a limited
number of newly hired employees. This group of employees includes
scientific and technical staff. These options are issued under the
Kiadis Pharma N.V. 2016 Share Option and Stock Appreciation Right
Plan (the “Plan”), and are subject to its terms. The options are
options to acquire ordinary Kiadis shares, whereby one option gives
the right to acquire one ordinary share. The option exercise price
shall be the average closing sales price at which ordinary Kiadis
shares are traded during the three trading days prior to the day
the option is granted.
On the date hereof, the total number of issued
and outstanding ordinary Kiadis shares is 40,041,489. If all of the
13,500 options are exercised, the total number of issued and
outstanding ordinary Kiadis shares would increase by 0.03%.
Dutch Translation/Nederlandse
vertaling
Kiadis Pharma N.V. ("Kiadis")
maakt bekend dat, volgend op de aankondiging op 2 november 2020 dat
Kiadis en Sanofi voorwaardelijke overeenstemming hebben bereikt
over het Bod, de Nederlandse regels met betrekking tot openbare
biedingen Kiadis verplichten om in een persbericht alle transacties
te publiceren met betrekking tot de gewone aandelen in haar
kapitaal, inclusief de uitgifte van opties of aandelen aan
werknemers. Dienovereenkomstig doet Kiadis de onderstaande
bekendmaking.
Op grond van toezeggingen die zijn aangegaan
vóór 2 november 2020 zal Kiadis in de periode tussen vandaag en 1
januari 2021 in totaal 13.500 opties uitgeven aan een beperkt
aantal nieuw aangenomen medewerkers. Deze groep medewerkers omvat
wetenschappelijk en technisch personeel. Deze opties worden
uitgegeven onder het Kiadis Pharma N.V. 2016 Aandelenoptie- en
Aandelen Appreciatie Recht Plan (het “Plan”), en
zijn onderhevig aan de daaraan verbonden voorwaarden. De opties
zijn opties ter verwerving van gewone aandelen Kiadis, waarbij één
optie het recht geeft om één gewoon aandeel te verwerven. De
uitoefenprijs van de optie is de gemiddelde slotverkoopkoers
waartegen gewone aandelen Kiadis worden verhandeld gedurende de
drie handelsdagen voorafgaand aan de dag waarop de optie wordt
toegekend.
Vandaag bedraagt het totaal aantal geplaatste en
uitstaande gewone aandelen Kiadis 40.041.489. Als alle 13.500
opties worden uitgeoefend, zou het totaal aantal geplaatste en
uitstaande gewone aandelen Kiadis met 0,03% toenemen.
Dit persbericht vormt een samenvatting
van het gepubliceerde Engelstalige persbericht. Bij eventuele
verschillen is de tekst van het Engelstalige persbericht altijd
leidend.
Contacts
Kiadis: Maryann
Cimino, Sr. Manager, Corporate Affairs Tel: +1 (617) 710-7305
m.cimino@kiadis.com |
LifeSpring Life Sciences
Communication:Leon Melens (Amsterdam)Tel: +31 538 16
427lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 203
950 9144 kiadis@optimumcomms.com |
About Kiadis
Founded in 1997, Kiadis is building a fully
integrated biopharmaceutical company committed to developing
innovative cell-based medicines for patients with life-threatening
diseases. With headquarters in Amsterdam, The Netherlands, and
offices and activities across the United States, Kiadis is
reimagining medicine by leveraging the natural strengths of
humanity and our collective immune system to source the best cells
for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
Forward Looking Statements
Certain statements, beliefs and opinions in this press release are
forward-looking, which reflect Kiadis' or, as appropriate, Kiadis'
officers' current expectations and projections about future events.
By their nature, forward-looking statements involve a number of
known and unknown risks, uncertainties and assumptions that could
cause actual results, performance, achievements or events to differ
materially from those expressed, anticipated or implied by the
forward-looking statements. These risks, uncertainties and
assumptions could adversely affect the outcome and financial
effects of the plans and events described herein. A multitude of
factors including, but not limited to, changes in demand,
regulation, competition and technology, can cause actual events,
performance, achievements or results to differ significantly from
any anticipated or implied development. Forward-looking statements
contained in this press release regarding past trends or activities
should not be taken as a representation that such trends or
activities will continue in the future. As a result, Kiadis
expressly disclaims any obligation or undertaking to release any
update or revisions to any forward-looking statements in this press
release as a result of any change in expectations or projections,
or any change in events, conditions, assumptions or circumstances
on which these forward-looking statements are based. Neither Kiadis
nor its advisers or representatives nor any of its subsidiary
undertakings or any such person's officers or employees guarantees
that the assumptions underlying such forward-looking statements are
free from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.